Golden Helix Integrates Copy Number Analysis into VarSeq Software

BOZEMAN, Mont. - Oct. 19, 2016 - PRLog -- Golden Helix, Inc. recently announced the availability of Copy Number Variation (CNV) analysis in its VarSeq software. The CNV capability is part of the VarSeq clinical reports package.

Golden Helix is providing a proven and trusted clinical reporting platform for hospitals and testing labs globally. The company continually strives to incorporate industry best practices into its software to allow users to conduct a wide range of workflows in both cancer and hereditary diseases. In an effort to broaden the types of mutations that can be analyzed, Golden Helix announced the incorporation of capabilities that will allow its clinical users to analyze CNVS. CNVs are a common cause of developmental delay and congenital abnormalities in humans. They also play a role in cancer.

"Our users want to detect both point mutations and CNVs in one sequencing clinical test, if possible at all", said Dr. Andreas Scherer, President and CEO of Golden Helix. "In our newest release we will give our users the ability to do exactly this. This opens up the possibility to reduce the complexity in a genetic testing lab by streamlining the analysis process."

The VarSeq Clinical Suite offers streamlined and integrated analysis, taking a sample from a VCF formatted file to a clinical report seamlessly. VarSeq's automated workflows allow labs to automate the process in order to create a high-throughput environment. Further, VSWarehouse provides centralized storage of all genomic data, providing the additional capability to search for variants, easily engineer complex queries and connect to other lab and hospital level applications.

About Golden Helix
Golden Helix has been delivering industry leading bioinformatics solutions for the advancement of life science research and translational medicine for over 17 years. Our innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from microarrays and next-generation sequencing. With our solutions, hundreds of the world's top pharmaceutical, biotech, and academic research organizations are able to harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, and advance the quest for personalized medicine. Golden Helix products and services have been cited in over 900 peer-reviewed publications. For more information, visit: http://goldenhelix.com/

Media contact:

Cheryl Rogers, Director of Marketing
Golden Helix, Inc.
406-999-0176
rogers@goldenhelix.com